EP1572174A1 - Application et traitement de la maladie d alzheimer - Google Patents

Application et traitement de la maladie d alzheimer

Info

Publication number
EP1572174A1
EP1572174A1 EP03815109A EP03815109A EP1572174A1 EP 1572174 A1 EP1572174 A1 EP 1572174A1 EP 03815109 A EP03815109 A EP 03815109A EP 03815109 A EP03815109 A EP 03815109A EP 1572174 A1 EP1572174 A1 EP 1572174A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
inhibitors
recapture
disease
bile acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03815109A
Other languages
German (de)
English (en)
French (fr)
Inventor
Thierry Canton
Laurent Pradier
Jesus Benavides
Hubert Heuer
Hans-Ludwig Schaefer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of EP1572174A1 publication Critical patent/EP1572174A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP03815109A 2002-12-12 2003-12-10 Application et traitement de la maladie d alzheimer Withdrawn EP1572174A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0215722 2002-12-12
FR0215722A FR2848452B1 (fr) 2002-12-12 2002-12-12 Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PCT/FR2003/003654 WO2004062652A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
EP1572174A1 true EP1572174A1 (fr) 2005-09-14

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03815109A Withdrawn EP1572174A1 (fr) 2002-12-12 2003-12-10 Application et traitement de la maladie d alzheimer

Country Status (22)

Country Link
EP (1) EP1572174A1 (es)
JP (1) JP2006514063A (es)
KR (1) KR20050084250A (es)
CN (1) CN1726016A (es)
AR (1) AR042354A1 (es)
AU (1) AU2003296802A1 (es)
BR (1) BR0317280A (es)
CA (1) CA2507945A1 (es)
CO (1) CO5700712A2 (es)
FR (1) FR2848452B1 (es)
HR (1) HRP20050534A2 (es)
MA (1) MA27500A1 (es)
MX (1) MXPA05005556A (es)
NO (1) NO20053341L (es)
NZ (1) NZ540496A (es)
PE (1) PE20040770A1 (es)
PL (1) PL377110A1 (es)
RS (1) RS20050420A (es)
RU (1) RU2005121909A (es)
TW (1) TW200503707A (es)
WO (1) WO2004062652A1 (es)
ZA (1) ZA200504656B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
ZA200603165B (en) 2003-11-03 2007-07-25 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
AU2005210004B2 (en) 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
EP2015750A2 (en) 2006-04-28 2009-01-21 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2937085B1 (en) * 2007-05-22 2019-07-10 Otsuka Pharmaceutical Co., Ltd. A medicament comprising a carbostyril derivative and donezepil for treating alzheimer's disease
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EA029581B1 (ru) * 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
AU3585397A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
CA2311356C (en) * 1998-01-28 2004-07-13 Warner-Lambert Company Method for treating alzheimer's disease
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
DE19825804C2 (de) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2001056579A1 (en) * 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004062652A1 *

Also Published As

Publication number Publication date
KR20050084250A (ko) 2005-08-26
CA2507945A1 (fr) 2004-07-29
CO5700712A2 (es) 2006-11-30
NO20053341L (no) 2005-09-07
NZ540496A (en) 2008-04-30
BR0317280A (pt) 2005-11-08
PL377110A1 (pl) 2006-01-23
AU2003296802A1 (en) 2004-08-10
JP2006514063A (ja) 2006-04-27
ZA200504656B (en) 2006-08-30
RU2005121909A (ru) 2006-01-20
NO20053341D0 (no) 2005-07-08
PE20040770A1 (es) 2004-12-10
FR2848452B1 (fr) 2007-04-06
MXPA05005556A (es) 2005-07-26
RS20050420A (en) 2007-04-10
TW200503707A (en) 2005-02-01
MA27500A1 (fr) 2005-08-01
AR042354A1 (es) 2005-06-15
CN1726016A (zh) 2006-01-25
HRP20050534A2 (en) 2006-11-30
WO2004062652A1 (fr) 2004-07-29
FR2848452A1 (fr) 2004-06-18

Similar Documents

Publication Publication Date Title
EP2991670B1 (en) Sobetirome in the treatment of myelination diseases
US8338382B2 (en) Method of treating impaired mitochondrial function
US20190343774A1 (en) Compositions and Methods for Treating Neurologic Disorders
JP2001521002A (ja) 脳の代謝機能不全のための栄養補充剤
EP1071422B1 (fr) Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson
WO1998056365A1 (fr) INHIBITEUR DU FACTEUR Xa SEUL OU EN COMBINAISON AVEC UN ANTIAGREGANT PLAQUETTAIRE, CONTRE LA THROMBOSE ARTERIELLE
ZA200504656B (en) Prevention and treatment of Alzheimer's disease
FR2896157A1 (fr) Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
WO2000007592A1 (fr) Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique
FR2822464A1 (fr) Derives biguanides et leurs applications en therapeutique
WO2009092892A2 (fr) Nouvelle composition pour traiter les effets secondaires des traitements anticancereux
WO2000006160A1 (fr) Traitement de la depression avec une combinaison de fluoxetine (prozac), pindolol (visken) et buspirone (buspar)
US20040138145A1 (en) Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
FR2954700A1 (fr) Utilisation de polysaccharides dans le traitement du stress et de l'anxiete
EP1523321B1 (fr) Utilisation d'extraits de ginkgo biloba pour favoriser la masse musculaire au detriment de la masse graisseuse
FR2888116A1 (fr) Derives de thiazoles pour traiter les dyskinesies
TW202042793A (zh) 神經變性疾病之預防或治療藥
FR2979543A1 (fr) Composition pharmaceutique, nutraceutique ou alimentaire et son utilisation
WO2003024460A1 (fr) Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3-beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin
Ronald Steriti Age Associated Mental Impairment
FR2845003A1 (fr) Utilisation de derives de thiazolidinedione comme inhibiteurs de l'aldose reductase
WO1988007368A2 (fr) Composition medicamenteuse pour le traitement et la prevention de maladies dues a une cytotoxicite a mediation cellulaire, renfermant au moins un derive de la pyridine comme principe actif
WO2004047564A1 (fr) Nouvelles compositions pharmaceutiques notamment pour la prevention des pathologies cardio-vasculaires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050712

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17Q First examination report despatched

Effective date: 20080304

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080715